GLP-1 therapy increases visceral adipose tissue metabolic activity: lessons from a randomized controlled trial in obstructive sleep apnea.

Autor: O'Donnell C; Pulmonary and Sleep Disorders Unit, St. Vincent's University Hospital, Dublin, Ireland.; School of Medicine, University College Dublin, Dublin, Ireland., Ryan O; Department of Endocrinology, St. Vincent's University Hospital, Dublin, Ireland.; St. Columcille's Hospital, Dublin, Ireland., Hogan AE; Kathleen Lonsdale Institute for Human Health Research, Maynooth University, Maynooth, Ireland., Killick D; Department of Endocrinology, St. Vincent's University Hospital, Dublin, Ireland., Crilly S; Department of Radiology, St. Vincent's University Hospital, Dublin, Ireland., Dodd JD; Department of Radiology, St. Vincent's University Hospital, Dublin, Ireland., Murphy DJ; School of Medicine, University College Dublin, Dublin, Ireland.; Department of Radiology, St. Vincent's University Hospital, Dublin, Ireland., Ryan S; Pulmonary and Sleep Disorders Unit, St. Vincent's University Hospital, Dublin, Ireland.; School of Medicine, University College Dublin, Dublin, Ireland., O'Shea D; School of Medicine, University College Dublin, Dublin, Ireland.; Department of Endocrinology, St. Vincent's University Hospital, Dublin, Ireland.; St. Columcille's Hospital, Dublin, Ireland.
Jazyk: angličtina
Zdroj: Obesity (Silver Spring, Md.) [Obesity (Silver Spring)] 2024 Aug 22. Date of Electronic Publication: 2024 Aug 22.
DOI: 10.1002/oby.24126
Abstrakt: Objective: Glucagon-like peptide-1 (GLP-1) analogues are currently the most widely used pharmacotherapies for weight loss. Their primary mechanism of action is attributed to reduction in energy intake. Data from murine studies also support an additional impact of those agents on energy homeostasis through upregulation of visceral adipose tissue (VAT) metabolic activity, but this remains uncertain in humans.
Methods: Here, we present data from a proof-of-concept study on 30 individuals with obstructive sleep apnea and obesity who were randomized to a GLP-1 therapy-based weight loss regimen, continuous positive airway pressure, or a combination of both for 24 weeks. At baseline and study completion, 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography-computed tomography (PET-CT) was performed to evaluate VAT metabolic activity, expressed as VAT target to background ratio.
Results: Treatment with GLP-1, but not with continuous positive airway pressure, was associated with a significant increase in VAT target to background ratio. There was a strong correlation between the increase in VAT metabolic activity and the degree of weight loss.
Conclusions: These data support the hypothesis that upregulation of VAT metabolic activity by GLP-1 contributes to its weight loss action in humans, and this subject warrants further detailed investigation.
(© 2024 The Author(s). Obesity published by Wiley Periodicals LLC on behalf of The Obesity Society.)
Databáze: MEDLINE
Externí odkaz: